What is Sitryx?
Headquartered in Oxford, UK, Sitryx operates at the intersection of immunology and metabolism. The company was established by a consortium of six world-leading researchers, including Houman Ashrafian and Luke O'Neill, who have collectively authored thousands of peer-reviewed papers. By focusing on the energetic status of immune cells, Sitryx aims to develop disease-modifying therapeutics that address unmet needs in oncology and inflammatory conditions. The company's business model leverages deep academic roots combined with a robust pipeline of projects, positioning it as a high-value player in the global biotechnology landscape.
How much funding has Sitryx raised?
Sitryx has raised a total of $69M across 2 funding rounds:
Series A
$30M
Other Financing Round
$39M
Series A (2018): $30M, investors not publicly disclosed
Other Financing Round (2023): $39M led by Lilly, Sofinnova Partners, and Oxford Sciences Enterprises
Key Investors in Sitryx
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company created to found, fund and build transformational businesses via a unique partnership with the University of Oxford, the world's leading research university.
What's next for Sitryx?
Looking ahead, the influx of capital is expected to accelerate the advancement of Sitryx's diverse pipeline through critical clinical development stages. The strategic alignment with major pharmaceutical partners, such as the collaboration with Eli Lilly and Company, provides a clear pathway for the commercialization of its research. As the company scales, the focus will likely shift toward optimizing its drug discovery platform and expanding its footprint in international markets. By maintaining its commitment to rigorous scientific inquiry and leveraging its strong syndicate of investors, Sitryx is well-positioned to translate its metabolic insights into transformative patient outcomes.
See full Sitryx company page
